Jiawan Wang1, Jan M Schilling, Ingrid R Niesman, John P Headrick, J Cameron Finley, Evan Kwan, Piyush M Patel, Brian P Head, David M Roth, Yun Yue, Hemal H Patel. 1. From the Department of Anesthesiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China (J.W., Y.Y.); VA San Diego Healthcare System, San Diego, California (P.M.P., B.P.H., D.M.R., H.H.P.); Department of Anesthesiology, University of California, San Diego, California (J.M.S., I.R.N., J.C.F., E.K., P.M.P., B.P.H., D.M.R., H.H.P.); and Heart Foundation Research Center, Griffith University, Gold Coast, Queensland, Australia (J.P.H.).
Abstract
BACKGROUND: Caveolae are a nexus for protective signaling. Trafficking of caveolin to mitochondria is essential for adaptation to cellular stress though the trafficking mechanisms remain unknown. The authors hypothesized that G protein-coupled receptor/inhibitory G protein (Gi) activation leads to caveolin trafficking to mitochondria. METHODS: Mice were exposed to isoflurane or oxygen vehicle (30 min, ± 36 h pertussis toxin pretreatment, an irreversible Gi inhibitor). Caveolin trafficking, cardioprotective "survival kinase" signaling, mitochondrial function, and ultrastructure were assessed. RESULTS: Isoflurane increased cardiac caveolae (n = 8 per group; data presented as mean ± SD for Ctrl versus isoflurane; [caveolin-1: 1.78 ± 0.12 vs. 3.53 ± 0.77; P < 0.05]; [caveolin-3: 1.68 ± 0.29 vs. 2.67 ± 0.46; P < 0.05]) and mitochondrial caveolin levels (n = 16 per group; [caveolin-1: 0.87 ± 0.18 vs. 1.89 ± .19; P < 0.05]; [caveolin-3: 1.10 ± 0.29 vs. 2.26 ± 0.28; P < 0.05]), and caveolin-enriched mitochondria exhibited improved respiratory function (n = 4 per group; [state 3/complex I: 10.67 ± 1.54 vs. 37.6 ± 7.34; P < 0.05]; [state 3/complex II: 37.19 ± 4.61 vs. 71.48 ± 15.28; P < 0.05]). Isoflurane increased phosphorylation of survival kinases (n = 8 per group; [protein kinase B: 0.63 ± 0.20 vs. 1.47 ± 0.18; P < 0.05]; [glycogen synthase kinase 3β: 1.23 ± 0.20 vs. 2.35 ± 0.20; P < 0.05]). The beneficial effects were blocked by pertussis toxin. CONCLUSIONS: Gi proteins are involved in trafficking caveolin to mitochondria to enhance stress resistance. Agents that target Gi activation and caveolin trafficking may be viable cardioprotective agents.
BACKGROUND: Caveolae are a nexus for protective signaling. Trafficking of caveolin to mitochondria is essential for adaptation to cellular stress though the trafficking mechanisms remain unknown. The authors hypothesized that G protein-coupled receptor/inhibitory G protein (Gi) activation leads to caveolin trafficking to mitochondria. METHODS:Mice were exposed to isoflurane or oxygen vehicle (30 min, ± 36 h pertussis toxin pretreatment, an irreversible Gi inhibitor). Caveolin trafficking, cardioprotective "survival kinase" signaling, mitochondrial function, and ultrastructure were assessed. RESULTS:Isoflurane increased cardiac caveolae (n = 8 per group; data presented as mean ± SD for Ctrl versus isoflurane; [caveolin-1: 1.78 ± 0.12 vs. 3.53 ± 0.77; P < 0.05]; [caveolin-3: 1.68 ± 0.29 vs. 2.67 ± 0.46; P < 0.05]) and mitochondrial caveolin levels (n = 16 per group; [caveolin-1: 0.87 ± 0.18 vs. 1.89 ± .19; P < 0.05]; [caveolin-3: 1.10 ± 0.29 vs. 2.26 ± 0.28; P < 0.05]), and caveolin-enriched mitochondria exhibited improved respiratory function (n = 4 per group; [state 3/complex I: 10.67 ± 1.54 vs. 37.6 ± 7.34; P < 0.05]; [state 3/complex II: 37.19 ± 4.61 vs. 71.48 ± 15.28; P < 0.05]). Isoflurane increased phosphorylation of survival kinases (n = 8 per group; [protein kinase B: 0.63 ± 0.20 vs. 1.47 ± 0.18; P < 0.05]; [glycogen synthase kinase 3β: 1.23 ± 0.20 vs. 2.35 ± 0.20; P < 0.05]). The beneficial effects were blocked by pertussis toxin. CONCLUSIONS: Gi proteins are involved in trafficking caveolin to mitochondria to enhance stress resistance. Agents that target Gi activation and caveolin trafficking may be viable cardioprotective agents.
Authors: John P Headrick; Laura Willems; Kevin J Ashton; Kirsten Holmgren; Jason Peart; G Paul Matherne Journal: J Physiol Date: 2003-04-25 Impact factor: 5.182
Authors: Yasuo M Tsutsumi; Yousuke T Horikawa; Michelle M Jennings; Michael W Kidd; Ingrid R Niesman; Utako Yokoyama; Brian P Head; Yasuko Hagiwara; Yoshihiro Ishikawa; Atsushi Miyanohara; Piyush M Patel; Paul A Insel; Hemal H Patel; David M Roth Journal: Circulation Date: 2008-10-20 Impact factor: 29.690
Authors: Supriyo Ray; Adam Kassan; Anna R Busija; Padmini Rangamani; Hemal H Patel Journal: Am J Physiol Cell Physiol Date: 2015-11-25 Impact factor: 4.249
Authors: Atsushi Sawada; Shanshan Wang; Minyu Jian; Joseph Leem; Jesse Wackerbarth; Junji Egawa; Jan M Schilling; Oleksandr Platoshyn; Alice Zemljic-Harpf; David M Roth; Hemal H Patel; Piyush M Patel; Martin Marsala; Brian P Head Journal: FASEB J Date: 2019-03-20 Impact factor: 5.191
Authors: Adam Kassan; Uyen Pham; Quynhmy Nguyen; Melissa E Reichelt; Eunbyul Cho; Piyush M Patel; David M Roth; Brian P Head; Hemal H Patel Journal: Am J Physiol Cell Physiol Date: 2016-10-05 Impact factor: 4.249
Authors: Jay Parikh; Alice Zemljic-Harpf; Johnny Fu; Dimosthenis Giamouridis; Tung-Chin Hsieh; Adam Kassan; Karnam S Murthy; Valmik Bhargava; Hemal H Patel; M Raj Rajasekaran Journal: J Sex Med Date: 2017-10 Impact factor: 3.802
Authors: Junhui Sun; Tiffany Nguyen; Angel M Aponte; Sara Menazza; Mark J Kohr; David M Roth; Hemal H Patel; Elizabeth Murphy; Charles Steenbergen Journal: Cardiovasc Res Date: 2015-02-18 Impact factor: 10.787
Authors: Kirsten F Smit; Gezina T M L Oei; Moritz Konkel; Quinten J J Augustijn; Markus W Hollmann; Benedikt Preckel; Hemal H Patel; Nina C Weber Journal: Cardiovasc Drugs Ther Date: 2019-06 Impact factor: 3.727